Soiken Holdings Inc. (TYO:2385)

Market Cap	6.64B +96.9%
Revenue (ttm)	4.58B -8.4%
Net Income	173.00M
EPS	6.61
Shares Out	26.16M
PE Ratio	38.41
Forward PE	n/a
Dividend	5.00 (1.98%)
Ex-Dividend Date	Jun 29, 2026

Volume	36,300
Average Volume	41,195
Open	254.00
Previous Close	253.00
Day's Range	254.00 - 259.00
52-Week Range	131.00 - 325.00
Beta	0.10
RSI	57.82
Earnings Date	May 13, 2026

About Soiken Holdings

Soiken Holdings Inc. engages in the development of biomarkers in Japan. It is involved in the development and sale of cosmetics and dietary supplements comprising imidapeptides; licensing and development of biomarker technology; provision of marketing research and post-marketing surveys for dietary supplements; and research, development, and sale of functional materials, such as lactoferrin, as well as pharmaceutical products from ascochlorin derivatives. The company also provides clinical evaluation tests for foodstuffs using biomarker technol...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1994
• Employees: 49
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 2385

Financial Performance

In fiscal year 2025, Soiken Holdings's revenue was 4.85 billion, a decrease of -6.01% compared to the previous year's 5.16 billion. Losses were -210.00 million, -68.28% less than in 2024.